Gabapentin for the treatment of painful diabetic neuropathy: dosing to achieve optimal clinical response
- 1 May 2004
- journal article
- Published by SAGE Publications in British Journal of Diabetes
- Vol. 4 (3), 173-178
- https://doi.org/10.1177/14746514040040030601
Abstract
Objective To determine whether gabapentin titrated to achieve clinical effect (≥ 50% reduction in pain; 900—3,600 mg/day) provides superior efficacy to a commonly prescribed fixed-dose (900 mg/day) in subjects with PDN. Methods In Latin America, an open-label trial randomised 339 subjects with PDN to gabapentin, 900 mg/day, for seven weeks (n=170), or to 900—3,600 mg/day titrated over four weeks to achieve clinical effect, followed by three weeks at stable dose (n=169). Results Gabapentin produced a significantly greater reduction in final weekly mean pain scores from baseline when titrated to clinical effect than when administered as a fixed-dose regimen (53.6% vs. 43.3%; p=0.009). Responder rate was significantly increased (64.5% vs. 47.5%; p=0.002), mean VAS scores significantly decreased, final weekly sleep interference scores significantly decreased (57% C vs. 37.2%; p=0.013), and trends favouring improvement in global functioning and QOL were seen in the titration to clinical effect group (p Conclusions Titration to clinical effect offered superior efficacy in treating PDN compared to a low fixed-dose treatment. Br J Diabetes Vasc Dis 2004;4:173—8Keywords
This publication has 36 references indexed in Scilit:
- Diabetes trends in Latin AmericaDiabetes/Metabolism Research and Reviews, 2002
- Anticonvulsants for Neuropathic Pain SyndromesDrugs, 2000
- The Novel Anticonvulsant Drug, Gabapentin (Neurontin), Binds to the α2δ Subunit of a Calcium ChannelJournal of Biological Chemistry, 1996
- The effect of gabapentin on brain gamma‐aminobutyric acid in patients with epilepsyAnnals of Neurology, 1996
- GabapentinClinical Neuropharmacology, 1995
- Effects of anticonvulsant drug gabapentin on the enzymes in metabolic pathways of glutamate and GABAEpilepsy Research, 1995
- Gabapentin (Neurontin) as Add‐on Therapy in Patients with Partial Seizures: A Double‐Blind, Placebo‐Controlled StudyEpilepsia, 1994
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- Gabapentin in partial epilepsyThe Lancet, 1990
- Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol®): Double blind crossover trialDiabetologia, 1969